CELL THERAPY FROM THE BENCH TO THE BEDSIDE AND RETURN

Fechas y lugar de celebración

Plazos

Objetivos

The aim of this course is the diffusion of knowledge about stem cells and their therapeutic possibilities, with a special emphasis on Hematopoietic Stem Cell Transplants and Regenerative Medicine.

The course is intended to provide a forum for scientific discussion with basic researchers and clinical experts in cell therapy, and to set out the achievements and challenges in this exciting new area of Medicine.

Specific Course Objectives are:

To analyse in depth the different types of stem cells, their biological properties, their laboratory manipulation and their clinical use.

To learn the new types of hematopoietic cell transplantation, and new approaches of immune modulation.

To discuss the present clinical trials of stem cell therapy for repairing organs and tissues.

Organización de la actividad

Dirección

Destinatarios

Hematologists and other medicine doctors, biomedical researchers, students, graduates and others interested in the subject

Datos generales

Precios

(*) El precio de 160€ incluye la comida / Price: 160€ lunch included

Programa

Lunes 2 Bone Marrow Stem Cells. Hematopoietic Stem Cell Transplantation

  • 09:00 h. Open Session.
  • 09:30 h. The Biology of the Hematopoietic Stem Cell.
    • Prof. Carlos Solano
      Head Hematology Dpt. University Clinic Hospital of Valencia. INCLIVA. University of Valencia, Spain.
  • 10:00 h. Procurement of Hematopoietic Progenitors: Cellular Selection.
    • Prof. Miguel Blanquer, MD
      Hematology Department. Institute of Biomedical Research of Murcia - IMIB, Virgen de la Arrixaca University Hospital. University of Murcia. Spain.
  • 10:30 h. Coffee Break.
  • 11:00 h. Hematopoietic cell transplantation: cell therapy to cure haematological diseases.
    • Prof. José M. Moraleda
      Professor of Medicine. University of Murcia. Head Dpt. of Hematology and HSCT Program. Institute of Biomedical Research of Murcia - IMIB, Virgen de la Arrixaca University Hospital. Murcia, Spain.
  • 11:30 h. Graft versus host disease. The Jekyl and Hyde of allotransplantation.
    • Prof. José Antonio Pérez Simón
      Professor of Hematology. Head Hematology Department. Institute of Biomedicine of Sevilla (IBIS), Virgen del Rocio University Hospital. University of Sevilla. Spain.
  • 12:00 h. The immunobiology of Cell therapy and the umbilical cord unique cells.
    • Prof. Alejandro Madrigal
      Scientific Director of The Anthony Nolan Trust. Chair of Hematology. Department of Hematology. The Royal Free and University College Medical School. London, UK.
  • 13:00 h. Lunch.
  • 15:00 h. Haploidentical transplants. The new frontier. Up to date results and new insights.
    • Prof. Rafael Duarte
      Department of Hematology. University Hospital Puerta de Hierro. Madrid, Spain.
  • 15:45 h. Debate session: What is the future of HSCT. Unsolved questions.
    • Is the transplant going to survive with the new immunotherapies?
      Prof. José Antonio Pérez Simón. Professor of Hematology. Head Hematology Department. Institute of Biomedicine of Sevilla (IBIS), Virgen del Rocio University Hospital. University of Sevilla. Spain.
    • Do we need the umbilical cord banks?
      Prof. Rafael Duarte. Department of Hematology. University Hospital Puerta de Hierro. Madrid, Spain.
    • Should I bank my baby's cord blood?
      Prof. Alejandro Madrigal. Scientific Director of The Anthony Nolan Trust. Chair of Hematology. Department of Hematology. The Royal Free and University College Medical School. London, UK.

Martes 3 Immunotherapy and new immunotherapeutic approaches

  • 09:00 h. Monoclonal Antibodies. The development of ''magic bullets''. Bispecific Mo Ab against leukemia.
    • Prof. Joaquín Martínez López
      Head Hematology Dpt. University Hospital 12 de Octubre. Professor of Medicine. Autonomous University, Madrid, Spain.
  • 09:30 h. PD1. A target molecule to revive the immune system against Hodgkin's disease.
    • Prof. Ramón García Sanz
      Professor of Medicine. University Hospital of Salamanca. Salamanca, Spain.
  • 10:00 h. CD38. A target molecule to fight against Myeloma.
    • Prof. Paula Rodríguez Otero
  • 10:30 h. Coffee Break.
  • 11:00 h. CAR T- cells. Basic principles and clinical Pharmacology.
    • Prof. Irene García Cadenas
      Hematology Dpt. Hospital Sant Pau. Institut José Carreras. University of Barcelona, Spain.
  • 11:30 h. CAR T- cells in Leukemia.
    • Prof. Álvaro Urbano
      MD. Director of Hematology Dpt. Institut José Carreras. University of Barcelona, Spain.
  • 12:00 h. CAR T- cells in Lymphoma.
    • Prof. Javier Briones Meijide
      Hematology Dpt. Hospital Sant Pau. Institut José Carreras. University of Barcelona. Spain.
  • 13:00 h. Lunch.
  • 15:00 h. CAR T- cells in Mieloma.
    • Prof. Estefanía García Guerrero
  • 15:30 h. Debate session: CAR T- cells and Inmunotherapy. Affordability of the new drugs and its economic impact in the national health system.
    • Prof. Jorge Sierra Gil
      Professor of Medicine. Head Dpt Hematology. University of Barcelona. University Hospital Santa Creu I Sant PauPresident of Spanish Hematology Society. Professor of Medicine University of Barcelona. Head Dpt. Hematology. University Hospital Santa Creu I Sant Pau. Barcelona. Spain.
    • Prof. Alejandro Madrigal
      Scientific Director of The Anthony Nolan Trust. Chair of Hematology. Department of Hematology. The Royal Free and University College Medical School. London, UK.
    • Prof. Carlos Solano
      Head Hematology Dpt. University Clinic Hospital of Valencia. INCLIVA. University of Valencia, Spain.
    • Prof. José Antonio Pérez Simón
      Professor of Hematology. Head Hematology Department. Institute of Biomedicine of Sevilla (IBIS), Virgen del Rocio University Hospital. University of Sevilla. Spain.
    • Prof. Felipe Prosper
      Director of Cell Therapy Department. Co-director Hematology Department. University of Navarra. Pamplona, Spain.
    • Prof. Jorge Gayoso Cruz
    • Prof. Sol Ruiz, PhD
      Head of the Unit of Biotechnology and Advanced Therapies. European Medicines Agency (EMA). Madrid, Spain.

Miércoles 4 Mesenchymal Stem Cells (MSC), induced Pluripotent Stem cells (iPSC), Gene therapy: Scientific basis for its therapeutic use

  • 09:00 h. MSC properties: the biological basis to become a cell medicine.
    • Prof. Agustín Zapata
      Professor of Cell Biology. Complutense University of Madrid. Spain.
  • 09:30 h. The extrinsic regulation of haematopoietic stem cells as a therapeutic target.
    • Prof. Simón Méndez Ferrer
      Department of Haematology, NHS-Blood and Transplant. Cambridge Biomedical Campus. University of Cambridge. UK.
  • 10:15 h. Stem cell trafficking. GPS to optimize MSC therapeutics.
    • Prof. Robert Sackstein
      Professor and Director of the Program of Excellence in Glycoscience, Harvard Medical School, Boston. Ma, USA.
  • 11:00 h. Coffee Break.
  • 11:30 h. Gene editing: A New tool for the future.
    • Prof. José Carlos Segovia PhD
      Differentiation and Cytometry Unit, Hematopoietic Innovative Therapies Division. CIEMAT. University of Madrid. Spain.
  • 12:00 h. Genetical manipulation of MSC to improve function.
    • Prof. Rosa María Yáñez González
      Hematopoietic Innovative Therapies Division. CIEMAT. University of Madrid. Spain.
  • 12:30 h. Genetically modified MSC to improve function. Animal models.
    • Prof. Mariano García Arranz
      Fundación Jiménez Díaz University Hospital. Autonomous University of Madrid. Spain.
  • 13:00 h. Lunch.
  • 15:00 h. iPSC as a Therapeutic Tool.
    • Prof. Ángel Raya
      Director Center of Regenerative Medicine in Barcelona (CMRB). Barcelona, Spain.
  • 15:30 h. Fucosylated MSC in the treatment of Inflammation.
    • Prof. David García Bernal
      Cell Therapy Unit and HSCT Program. Virgen de la Arrixaca University Hospital. University of Murcia - IMIB. Murcia, Spain.
  • 16:00 h. Production of cells in GMP facilities: realities and challenges for the future.

Jueves 5 Cell Therapy and tissue engineering. Clinical Trials

  • 09:00 h. Cell Therapy in Cardiac Diseases.
    • Prof. Felipe Prosper
      Director of Cell Therapy Department. Co-director Hematology Department. University of Navarra. Pamplona, Spain.
  • 09:30 h. Cell Therapy in Diabetes Mellitus.
    • Prof. Bernat Soria
      Director of the Stem Cells Department of the Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER). University Pablo de Olavide. Sevilla, Spain.
  • 10:00 h. Cell Therapy for Osteoarticular Repair.
    • Prof. Javier García-Sancho
      Professor of Physiology. School of Medicine. Institute of Biology and Molecular Genetics (IBGM). University of Valladolid. Spain.
  • 10:30 h. Coffee Break.
  • 11:00 h. Therapy -Regenerative Medicine- in musculoskeletal system.
    • Prof. Juan Manuel López-Alcorocho
      Clinical Research Unit, CEMTRO Hospital. Madrid, Spain.
  • 11:30 h. Cell Therapy and Microvesicles for Treatment of Transplant Rejection and GVHD.
    • Prof. Fermín Sánchez-Guijo, MD
      Hematology Department. University Hospital of Salamanca. University of Salamanca. Spain.
  • 12:00 h. Cell Therapy in Odontology.
  • 12:30 h. Lunch.
  • 14:30 h. Cell Therapy to improve Healing in Surgery. The road map to success.
    • Prof. Damián García Olmo
      Prof. of Surgery. Chief of Dept. of Surgery. Fundation Jiménez Díaz University Hospital. Autonomous University of Madrid. Spain.
  • 15:15 h. Cell therapy and bioengineering for skin diseases.
    • Prof. Marcela del Río
      Professor of Biology. Bioengineering Dpt. Regenerative Medicine and tissue engineering group, CIEMAT, FJD, CIBERER. Carlos III University. Madrid, Spain.
  • 16:00 h. Key question conference: ''Negotiate in difficult times''.
    • Dr. Jesús Ángel Loza Aguirre
      Ex-Member of the Basque Parliament. Commisioned for coexistence in Euskadi. Hematologist.

Viernes 6 Cell Therapy in Neurological Diseases

  • 09:00 h. Cell replacement therapy for Parkinson's disease.
    • Prof. José Luis Labandeira García
  • 09:30 h. Antiparkinsonian cell therapy using carotid body cells.
    • Prof. Juan José Toledo
      Professor of Physiology. Director of the Dpt of Medical Physiology and Biophysics. Institute of Biomedical Research of Seville. IBiS, Virgen del Rocio Hospital/CSIC/University of Sevilla. Spain.
  • 10:00 h. Cell therapy in Friedrich Ataxia a new model of neural regeneration.
    • Prof. Salvador Martínez
      Director Institute of Neurosciences. UMH-CSIC. Professor of Human Anatomy and Embryology. University Miguel Hernández. Elche, Spain.
  • 10:30 h. Coffee Break.
  • 11:00 h. Cell Therapy for Amyotrophic Lateral Sclerosis. Where we stand and were we go.
    • Prof. Letizia Mazzini
      Head of the tertiary ALS Center. Department of Neurology, Eastern Piedmont University, Maggiore della Carità Hospital. Novara, Italy.
  • 11:30 h. Gene Therapy: clinical developments.
    • Prof. Juan Antonio Bueren Roncero
      Head of the Division of Hematopoiesis and Gene Therapy Division. CIEMAT. University of Madrid. Madrid, Spain.
  • 12:00 h. Gene Therapy for Alzheimer disease.
    • Prof. Nathalie Cartier
      Research Director. INSERM. París, France.
  • 13:00 h. Lunch.
  • 15:00 h. Debate session: the cell therapy tourism and fraud. Ethical and regulatory aspects.
    • The opinion of the AEMPS.
      Prof. Sol Ruiz, PhD. Head of the Unit of Biotechnology and Advanced Therapies. European Medicines Agency (EMA). Madrid, Spain.
    • The opinion of the scientists.
      Prof. Salvador Martínez. Director Institute of Neurosciences. UMH-CSIC. Professor of Human Anatomy and Embryology. University Miguel Hernández. Elche, Spain.
      Prof. Letizia Mazzini. Head of the tertiary ALS Center. Department of Neurology, Eastern Piedmont University, Maggiore della Carità Hospital. Novara, Italy.
  • 16:00 h. Closing ceremony and awarding of certificates.

Aclaraciones

The Course has been declared of Scientific and Medical Interest by the Public Health System of Murcia.



Colaboradores

AMGEN
AMGEN

RED TERCEL
RED TERCEL

MSD
MSD

Gilead
Gilead

Janssen
Janssen

S.E.H.H.
S.E.H.H.

Celgene
Celgene

Pfizer
Pfizer

SANOFI
SANOFI

nirco
nirco

TAKEDA
TAKEDA

Novartis
Novartis

Bristol-Myers Squibb
Bristol-Myers Squibb

Jazz Pharmaceuticals
Jazz Pharmaceuticals

Kern Pharma
Kern Pharma

novo nordisk
novo nordisk

abbvie
abbvie